ARMO Biosciences Inc (ARMO):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ARMO Biosciences Inc (ARMO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8281
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:33
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ARMO Biosciences Inc (ARMO Biosciences) is an immuno-oncology company that develops tumors treatment drugs. Its pipeline drug candidates include AM0010, AM0015, AM0012, AM0003 and AM0001. ARMO Biosciences’s lead immunotherapy AM0010 is along-acting form of recombinant human Interleukin 10 (IL-10). The company’s AM0001, is a monoclonal antibody that activates T cells by blocking the interaction between the checkpoint inhibitors programmed cell death protein-1 and programmed cell death ligand-1. Its pipeline comprises various validated product candidates aimed at treating a variety of cancers in combination with standard of care and emerging immunotherapies. ARMO Biosciences is headquartered in Redwood City, California, the US.

ARMO Biosciences Inc (ARMO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ARMO Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Armo Biosciences Completes Acquisition Of Prevascar Assets Of Renovo For US$0.7 Million 11
Venture Financing 12
ARMO Biosciences Raises USD67 Million in Series C-1 Financing 12
Armo Biosciences Raises USD50 Million in Series C Financing 14
Armo Biosciences Raises USD30 Million in Series B Financing 16
ARMO Biosciences Raises US$20 Million In Series A Financing 18
Licensing Agreements 20
ARMO BioSciences Enters into Licensing Agreement with Open Monoclonal 20
ARMO Biosciences Enters into Licensing Agreement with Merck 21
Equity Offering 22
ARMO BioSciences Raises USD128 Million in IPO 22
Acquisition 24
Eli Lilly Acquires ARMO Biosciences for USD1.6 Billion 24
ARMO Biosciences Inc – Key Competitors 26
ARMO Biosciences Inc – Key Employees 27
ARMO Biosciences Inc – Locations And Subsidiaries 28
Head Office 28
Recent Developments 29
Financial Announcements 29
Apr 02, 2018: ARMO BioSciences Reports FY 2017 Financial Results 29
Corporate Communications 30
Nov 28, 2017: ARMO BioSciences Appoints Herb Cross as Chief Financial Officer 30
Jun 28, 2017: ARMO BioSciences Appoints Naiyer A. Rizvi, M.D. to Board of Directors 31
Apr 26, 2017: ARMO BioSciences Appoints Pierre Legault to Board of Directors 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ARMO Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ARMO Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 8
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Armo Biosciences Completes Acquisition Of Prevascar Assets Of Renovo For US$0.7 Million 11
ARMO Biosciences Raises USD67 Million in Series C-1 Financing 12
Armo Biosciences Raises USD50 Million in Series C Financing 14
Armo Biosciences Raises USD30 Million in Series B Financing 16
ARMO Biosciences Raises US$20 Million In Series A Financing 18
ARMO BioSciences Enters into Licensing Agreement with Open Monoclonal 20
ARMO Biosciences Enters into Licensing Agreement with Merck 21
ARMO BioSciences Raises USD128 Million in IPO 22
Eli Lilly Acquires ARMO Biosciences for USD1.6 Billion 24
ARMO Biosciences Inc, Key Competitors 26
ARMO Biosciences Inc, Key Employees 27

List of Figures
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[ARMO Biosciences Inc (ARMO):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • ING-DiBa AG:企業の戦略的SWOT分析
    ING-DiBa AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Landeskreditbank Baden-Wuerttemberg-Foerderbank:企業の戦略・SWOT・財務分析
    Landeskreditbank Baden-Wuerttemberg-Foerderbank - Strategy, SWOT and Corporate Finance Report Summary Landeskreditbank Baden-Wuerttemberg-Foerderbank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, o …
  • Extendicare Inc (EXE):企業の財務・戦略的SWOT分析
    Summary Extendicare Inc (Extendicare), formerly Crownx Inc is a healthcare service provider that offers long-term care services. The center’s services include short stay care, convalescent care, home health care, group purchasing, assisted living, retirement living, workplace health and wellness, sk …
  • Impresa Pizzarotti & C. S.p.A.:企業の戦略・SWOT・財務情報
    Impresa Pizzarotti & C. S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Impresa Pizzarotti & C. S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Toleranzia AB-製薬・医療分野:企業M&A・提携分析
    Summary Toleranzia AB (Toleranzia) is a developer of platform technology for the treatment of autoimmune diseases. The company develops and offers products and technologies including Re-Tolerogen for the treatment of autoimmune diseases. Its Re-Tolerogen platform technology is a fusion protein for t …
  • Bank Pekao SA:戦略・SWOT・企業財務分析
    Bank Pekao SA - Strategy, SWOT and Corporate Finance Report Summary Bank Pekao SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • FMR LLC:企業の戦略的SWOT分析
    FMR LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Absher Construction Company:企業の戦略・SWOT・財務情報
    Absher Construction Company - Strategy, SWOT and Corporate Finance Report Summary Absher Construction Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Kbc Bank Ireland Plc
    Kbc Bank Ireland Plc - Strategy, SWOT and Corporate Finance Report Summary Kbc Bank Ireland Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Nikon Corporation:企業の戦略・SWOT・財務情報
    Nikon Corporation - Strategy, SWOT and Corporate Finance Report Summary Nikon Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • CanAlaska Uranium Ltd (CVV):企業の財務・戦略的SWOT分析
    Summary CanAlaska Uranium Ltd (CanAlaska) is a mining and mineral exploration and development company that acquires, explores and develops uranium properties in Athabasca basin of Canada. The company offers projects such as Diamond projects, Cree East project, Fond du Lac project, West McArthur proj …
  • Cell Therapy Catapult Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Cell Therapy Catapult Ltd (Catapult) is a provider of cell and gene therapy life cycle solutions. The company offers services such as industrialization, manufacturing, regulatory, health economics and market access, non-clinical safety and clinical operations. Its health economics and market …
  • Granules India Ltd (GRANULES):製薬・医療:M&Aディール及び事業提携情報
    Summary Granules India Ltd (Granules) is a pharmaceutical manufacturing company, which carries out the research, development and manufacture of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs) and finished dosages (FDs). The company manufactures Paracetomol, …
  • IRB Infrastructure Developers Ltd:企業の戦略・SWOT・財務情報
    IRB Infrastructure Developers Ltd - Strategy, SWOT and Corporate Finance Report Summary IRB Infrastructure Developers Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Monteloeder S.L.:戦略・SWOT・企業財務分析
    Monteloeder S.L. - Strategy, SWOT and Corporate Finance Report Summary Monteloeder S.L. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Chart Industries Inc (GTLS):企業の財務・戦略的SWOT分析
    Chart Industries Inc (GTLS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • SELEX Galileo Inc.:企業の戦略・SWOT・財務分析
    SELEX Galileo Inc. - Strategy, SWOT and Corporate Finance Report Summary SELEX Galileo Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Corby Spirit and Wine Limited:企業の戦略・SWOT・財務分析
    Corby Spirit and Wine Limited - Strategy, SWOT and Corporate Finance Report Summary Corby Spirit and Wine Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Kier Group plc (KIE):企業の財務・戦略的SWOT分析
    Kier Group plc (KIE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • GDI Integrated Facility Services Inc (GDI):企業の財務・戦略的SWOT分析
    Summary GDI Integrated Facility Services Inc (GDI), formery Medwell Capital Corp is a commercial facility service provider. The company’s services include cleaning, food plant sanitation, technical trade services and energy management, healthcare sanitation, hotel support, event support and disaster …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆